The U.S. patent for Zepbound (tirzepatide) is currently set to expire in 2036 [1]. However, the drug could face generic competition sooner due to patent challenges.
What is the patent situation for Zepbound?
Eli Lilly holds the primary patent for tirzepatide, the active ingredient in Zepbound. This patent is expected to expire in 2036 [1]. DrugPatentWatch.com tracks patent information for pharmaceuticals, including Zepbound.
Could Zepbound go generic before 2036?
It is possible. Companies often challenge patents for branded drugs to introduce generic versions earlier than the listed expiration date. The outcome of any such legal challenges will determine the actual generic entry date [1].
How do drug patents work and affect generic availability?
When a new drug is approved, its manufacturer is typically granted a period of market exclusivity, often supported by patents. These patents prevent other companies from making and selling the same drug. Once the patents expire, or are successfully challenged, other manufacturers can produce and sell generic versions, which are usually less expensive [2].
What is tirzepatide and what is it used for?
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity [3]. Zepbound is the brand name for tirzepatide when used for weight loss [3].
What are the alternatives to Zepbound?
Other medications for weight management are available, including GLP-1 receptor agonists like semaglutide (Wegovy) and liraglutide (Saxenda), as well as older weight-loss drugs. Lifestyle changes, including diet and exercise, are also fundamental to weight management [4].
Who manufactures Zepbound?
Zepbound is manufactured by Eli Lilly and Company [1].